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Abstract
Connexin 43 (Cx43), which is highly expressed in the heart and especially in cardiomyocytes, interferes with the expression of nitric oxide syn-
thase (NOS) isoforms. Conversely, Cx43 gene expression is down-regulated by nitric oxide derived from the inducible NOS. Thus, a complex
interplay between Cx43 and NOS expression appears to exist. As cardiac mitochondria are supposed to contain a NOS, we now investigated the
expression of NOS isoforms and the nitric oxide production rate in isolated mitochondria of wild-type and Cx43-deficient (Cx43Cre-ER(T)/fl) mice
hearts. Mitochondria were isolated from hearts using differential centrifugation and purified via Percoll gradient ultracentrifugation. Isolated
mitochondria were stained with an antibody against the mitochondrial marker protein adenine-nucleotide-translocator (ANT) in combination
with either a neuronal NOS (nNOS) or an inducible NOS (iNOS) antibody and analysed using confocal laser scanning microscopy. The nitric
oxide formation was quantified in purified mitochondria using the oxyhaemoglobin assay. Co-localization of predominantly nNOS (nNOS:
93  4.1%; iNOS: 24.6  7.5%) with ANT was detected in isolated mitochondria of wild-type mice. In contrast, iNOS expression was
increased in Cx43Cre-ER(T)/fl mitochondria (iNOS: 90.7  3.2%; nNOS: 53.8  17.5%). The mitochondrial nitric oxide formation was reduced in
Cx43Cre-ER(T)/fl mitochondria (0.14  0.02 nmol/min./mg protein) in comparison to wild-type mitochondria (0.24  0.02 nmol/min./mg).
These are the first data demonstrating, that a reduced mitochondrial Cx43 content is associated with a switch of the mitochondrial NOS isoform
and the respective mitochondrial rate of nitric oxide formation.
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Introduction
Connexin 43 (Cx43) is a gap junction protein, which is composed of
four transmembrane domains, two extracellular and one intracellular
loop, as well as cytosolic amino- and carboxy-termini. Cx43 is the tar-
get of different kinases and several phosphorylation sites are located
within the carboxy-terminus. As the predominant protein of ventricu-
lar gap junctions, Cx43 forms hemichannels at the plasma membrane
and regulates electrical cell coupling via gap junctions in myocardium.
Cx43 is also present at the inner membrane of cardiomyocyte subsar-
colemmal mitochondria (SSM), but not in interfibrillar mitochondria
(IFM) [1]. Cx43 is involved in cardioprotective signalling pathways [2]
and reduction of mitochondrial Cx43 abrogates cardioprotection by
ischaemic preconditioning [3]. Nitric oxide is involved in cardiopro-
tective signalling pathways and plays a central role in cardioprotection
by ischaemic preconditioning [2, 4, 5]. In the myocardium, nitric
oxide is produced by different nitric oxide synthase (NOS) enzymes:
neuronal NOS (nNOS), endothelial NOS (eNOS), inducible NOS (iNOS)
and mitochondrial NOS (mtNOS) [6–8]. The nNOS, eNOS and mtNOS
are calcium sensitive and constitutively active, while iNOS is calcium
insensitive and inducible. Nitric oxide is involved in the regulation of
myocardial contractility, which is enhanced by low concentrations
[9, 10] and depressed by high concentrations [11]. The mtNOS-
dependent nitric oxide serves as mediator in the regulation of the
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energy metabolism, whereas it is notably associated with complex I
(NADH dehydrogenase) and complex IV (cytochrome c oxidase) of
the respiratory chain [12]. In isolated mitochondria, mtNOS-
dependent nitric oxide reversibly inhibits the cytochrome c oxidase
[13, 14], reduces the mitochondrial oxygen consumption and
consequently ATP synthesis [15]. After myocardial infarction, the
expression, the activity and the localization of nNOS is changed
[16–18]. In cardiomyocytes, sarcoplasmatic reticulum localized nNOS
translocates to the sarcolemma and into mitochondria [19, 20].
The activated cardioprotective nitric oxide signalling pathway
results in increased production of S-nitrosothiols (SNO). The S-nitrosy-
lation is a modification of protein sulfhydryl residues by nitric oxide.
This reaction changes the structure and activity of mitochondrial pro-
teins in cardiomyocytes and protects proteins against irreversible oxi-
dative injury during reperfusion [21, 22]. One of these proteins is
mitochondrial complex I: the reversible inhibition of mitochondrial
complex I by S-nitrosylation is cardioprotective by limiting reactive
oxygen species (ROS) formation during reperfusion [23–25]. Reduc-
tion of NOS-dependent nitric oxide formation through NOS inhibition
abolishes the cardioprotection [26–28].
As yet, an interaction between nitric oxide and Cx43 is only
described at the cellular level. Gene expression of Cx43 is down-regu-
lated by iNOS-mediated nitric oxide formation [29–31]. Conversely, a
decreased nNOS expression by a reduction in Cx43 expression was
demonstrated in mice bladder cells [32], in cultured cardiomyocytes
[33] and astrocytes [34]. How in detail Cx43 expression alters nNOS
expression remains to be established, but the carboxy-terminus of
Cx43 functions as transcription factor [35] and thus might bind to the
promoter region of the nNOS gene. Interactions between Cx43 and
nitric oxide in mitochondria are still completely unclear.
Therefore, the aim of this study was to investigate a Cx43-depen-
dent alteration of NOS-mediated nitric oxide formation in cardiac
mitochondria. As mitochondria are supposed to contain a NOS, an
important way by which more insight into this mechanism of action
could be obtained, is investigation of mitochondrial NOS isoform
expression and measurement of mitochondrial nitric oxide formation
rate in isolated mitochondria of wild-type and Cx43-deficient
(Cx43Cre-ER(T)/fl) mouse hearts.
Materials and methods
Animal model
The present study was in accordance with the German laws for animal
welfare and approved by the local review committee. It conforms to the
Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH publication No. 85-23, revised 1996).
For experiments, 12–24-week-old male C57BL/6J wild-type (Charles
River Laboratories) and heterozygous Cx43Cre-ER(T)/fl mice (B6.129-
Gja1tm1Kdr, JAX mice; Bar Harbor, ME) were used. Heterozygous
Cx43Cre-ER(T)/fl mice have the same phenotype as wild-type mice. The het-
erozygous knockout mice for Cx43 were generated by replacing exon-2 of
the Cx43 gene by neomycin resistance gene [36]. The Cx43 expression in
mitochondria was characterized by Western blot. Cx43Cre-ER(T)/fl mice
showed lower mitochondrial Cx43 levels than wild-type mice (Fig. 2A and
B). As negative control served nNOS/ mice, which were provided by Dr.
Martin Szibor from Bad Nauheim, Germany as a gift. The right ventricles
were used as positive controls in Western blot analyses. Left ventricles
(LV) were used for the isolation of mitochondria.
Mitochondrial isolation
The mouse hearts were rapidly removed after cervical dislocation and
SSM were isolated from ventricles as previously described [37] using a
modification of the protocol described by Holmuhamedov et al. [38]
and IFM were isolated as previously described [1] according to a modi-
fied protocol by Judge et al. [39]. Isolated SSM were used for immuno-
cytochemical analyses. For Western blot analysis and nitric oxide
measurements, SSM and IFM were further purified by Percoll gradient
(30%) ultracentrifugation (35,000 9 g, 30 min.) for enrichment of
mitochondrial proteins and elimination of other cellular elements. The
protein concentration of the supernatant was determined using the Dc
protein assay (Bio-Rad, Hercules, CA, USA).
To rule out putative mitochondrial contamination with NOS isoforms
attached to the outer membrane of mitochondria, mitoplasts were pre-
pared by removing the outer membrane using the digitonin detergent
(2 mmol/l). The difference between mitochondria and mitoplasts was
shown by the content of voltage-dependent anion channel (VDAC), a
marker for the outer mitochondrial membrane. The presence of ATP-
synthase a, manganese superoxide dismutase (MnSOD) and Cx43
proved the intactness of mitoplasts.
Western blot analysis
For Western blot analysis, 100 lg of mitochondrial proteins were elec-
trophoretically separated on 10% SDS-PAGE and transferred to nitrocel-
lulose membranes. After blocking, the membranes were incubated with
the following antibodies: rabbit polyclonal anti-rat Cx43 (Invitrogen,
Carlsbad, CA, USA), ATP-synthase a (BD Transduction, San Jose, CA,
USA), rabbit polyclonal anti-human MnSOD (Upstate, Lake Placid, NY,
USA), rabbit polyclonal anti-human VDAC (Abcam, Cambridge, UK) or
mouse monoclonal anti-rabbit Na+/K+-ATPase (Upstate), mouse mono-
clonal anti-dog sarcoplasmatic calcium (SERCA2)-ATPase (Sigma-
Aldrich, Saint Louis, MO, USA). Immunoreactive signals were detected
by chemiluminescence (SuperSignal West Femto Maximum Sensitivity
Substrate, Pierce, Rockford, Il, USA) and quantified with the Scion
Image software (Frederick, ML, USA).
Immunocytochemistry
For immunocytochemistry, purified SSM were incubated simultaneously
with the following primary antibodies: anti-Cx43 (rabbit polyclonal anti-
rat Cx43, Zytomed, Berlin, Germany) with anti-cyclophilin D (mouse
monoclonal anti-rat, MitoSciences, Eugene, OR, USA), anti-nNOS (BD
Transduction) or anti-iNOS (BD Transduction) with anti-ANT (Santa
Cruz, Heidelberg, Germany) respectively. After washing, SSM were
incubated with corresponding secondary antibodies (TRITC donkey anti-
rabbit and FITC goat anti-rabbit for Cx43, TRITC donkey anti-rabbit and
FITC goat antimouse for nNOS, TRITC bovine antimouse and FITC
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bovine anti-rabbit for iNOS). SSM were examined by confocal laser scan
microscopy (Pascal, Zeiss, Jena, Germany, or Leica TCSSP2AOBS,
Wetzlar, Germany) at 630 9 magnification.
Measurement of cardiac nitric oxide
Oxyhaemoglobin assay
The nitric oxide formation in SSM (0.86 mg/ml) of wild-type mouse
hearts was measured by the oxyhaemoglobin assay. The oxyhaemoglo-
bin assay was modified to Feelisch et al. [40]. The nitric oxide forma-
tion was evaluated as the change in the absorbance at 401 and 590 nm
using a diode array spectrophotometer (HP 8453; Hewlett Packard,
Waldbronn, Germany). SSM, IFM or mitoplasts were incubated in incu-
bation buffer (pH 7.4) with L-arginine (1 mmol/l), BH4 (10 lmol/l),
CaCl2 (100 lmol/l) and oxyhaemoglobin (HbO2, 50 lmol/l) for 60 min.
at 37°C. SOD (1 U/ml) and catalase (50 U/ml) were also present in the
reaction medium to avoid unspecific reactions. SOD catalysed superox-
ide to oxygen and hydrogen peroxide. Catalase dissipated the hydrogen
peroxide in oxygen and water.
Every 10 min., an aliquot was diluted in isolation buffer (pH 7.4) and
the oxidation of HbO2 to methaemoglobin by nitric oxide was measured.
The nitric oxide scavenger carboxy-PTIO (2-(4-Carboxyphenyl)-4,4,5,5-
tetramethylimidazoline-1-oxyl-3-oxide) was used to determine the speci-
ficity of the nitric oxide signal. NOS-dependent nitric oxide formation
was confirmed by the selective NOS inhibitors SMTC and 1400 W
(selective for nNOS/iNOS) [41, 42].
Electron spin resonance spectroscopy
Mitochondrial nitric oxide content was also measured using electron spin
resonance spectroscopy (ESR) in isolated SSM. An aqueous spin trapping
solution Fe2+–(MGD)2 was prepared before each experiment as described
[4, 43]. GSNO was resolved in phosphate buffer (35 mg/ml) and used as
positive control. Isolated SSM and GSNO (200 lmol/l) were treated with
L-arginine (1 mmol/l), BH4 (10 lmol/l), CaCl2 (100 lmol/l), SOD (1 U/ml)
and catalase (50 U/ml) and Fe2+–(MGD)2 and incubated for 10 min. at
37°C. The prepared samples were then placed into quartz ESR tubes and
frozen immediately in liquid nitrogen. Samples were assayed for ESR
spectra of the relatively stable nitric oxide–Fe2+–(MGD)2 adduct. ESR
spectra were recorded with a ECS106 spectrometer (Bruker, Rheinstetten,
Germany) operating at X band with 100 kHz modulation frequency at a
temperature of 160 K, using 10 mW microwave power to avoid satura-
tion. Scans were traced with 2.85 G modulation amplitude, 340 G sweep
width, and 3356 G central field as described [44, 45]. Analysis of nitric
oxide content was performed with double integration of the nitric oxide
signal as described previously [46].
Statistics
Data are reported as mean  SEM. Confocal laser scanning microscopy
data for Cx43, nNOS and iNOS were compared by two-way ANOVA, sub-
sequent Bonferroni test. Quantitative Western blot data for Cx43 and
ATP-synthase a were compared by one-way ANOVA. The nitric oxide for-
mation by the oxyhaemoglobin assay and the ESR spectroscopy in SSM
of wild-type, Cx43Cre-ER(T)/fl and nNOS/ mice was compared by one-
way ANOVA respectively. A P < 0.05 was considered to indicate a signifi-
cant difference.
Results
NOS expression in SSM of Cx43-deficient mice
Confocal laser scanning microscopy demonstrated mainly nNOS
immunoreactivity and a weak expression of iNOS in isolated SSM
from wild-type mice (Fig. 1A). Conversely, in SSM of Cx43Cre-ER(T)/fl
mice, iNOS immunoreactivity was increased while nNOS expression
was reduced (Fig. 1A). As marker for mitochondria, the inner mito-
chondrial membrane protein ANT was detected. The statistical evalua-
tion of NOS expression showed a significant difference between
mitochondria expressing nNOS and iNOS in wild-type mice
(93  4.1% versus 24.6  7.5% co-localization of NOS with ANT,
n = 7 individual preparations, Fig. 1B). The nNOS expression in SSM
of Cx43Cre-ER(T)/fl mice (53.8  17.5% co-localization of NOS with
ANT, n = 7 individual preparations) was also significantly reduced
compared to wild-type mice. In contrast, the iNOS expression
(90.7  3.2% co-localization of NOS with ANT, n = 7 individual prep-
arations, Fig. 1B) in SSM of Cx43Cre-ER(T)/fl mice was significantly
increased compared to iNOS in wild-type mice.
To verify the immunocytochemical results by Western blot analy-
sis in the mitochondrial samples of wild-type and Cx43Cre-ER(T)/fl mice,
immunoblotting with anti-nNOS antibody against the amino-terminus
showed no distinctive band at 160 kD compared to the positive con-
trol (right ventricle, Fig. 2A). Only an unspecific band at 140 kD,
which was also seen in mitochondria of nNOS/ mice (negative con-
trol), was present (Fig. 2A). Antibodies against the iNOS isoform
showed no visible band. Mitochondria were not contaminated with
proteins of sarcolemma and with sarcoplasmatic reticulum as shown
by the absence of Na+/K+-ATPase and SERCA immunoreactivity
(Fig. 2A). Cx43 protein content was normalized to mitochondrial mar-
ker protein ATP-synthase a (Fig. 2B). Immunoprecipitation analysis
also showed no detectable signal of the NOS isoforms. By definition,
mitochondrial Cx43 expression in Cx43Cre-ER(T)/fl mice was signifi-
cantly reduced compared to wild-type mice.
Nitric oxide formation in Cx43-deficient mice
Nitric oxide formation was measured by the oxyhaemoglobin assay in
SSM of wild-type mice (Fig. 3). The basal NOS activity resulted in a
nitric oxide formation of 0.24  0.02 nmol/min./mg protein
(n = 15). The specificity of the nitric oxide signal was shown by the
nitric oxide scavenger PTIO. Inhibition of nNOS using the non-selec-
tive (W7) or the selective nNOS inhibitor (SMTC) resulted in a signifi-
cant reduction of the mitochondrial nitric oxide formation.
Digitonin treatment of mitochondria significantly reduced the con-
tent of the outer mitochondrial membrane protein VDAC to
14  2.6% (n = 6) of the signal of untreated mitochondria (set as
100%, Fig. 4A). The unchanged level of ATP-synthase a (93  27%
protein content of mitoplasts compared to mitochondria set as 100%,
n = 6), MnSOD (116  18%, n = 6) and mitochondrial Cx43
(105  27%, n = 6) confirmed an intact inner membrane of
mitoplasts (Fig. 4B). The nitric oxide production in mitoplasts was
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A B
Fig. 2 Expression of nNOS in subsarcolemmal mitochondria. (A) The expression of nNOS is presented in isolated subsarcolemmal mitochondria
(SSM) of Cx43Cre-ER(T)/fl (n = 9) and wild-type mice (n = 7). Right ventricles (RV) from wild-type and nNOS/ mice served as positive and negative
control. Na+/K+-ATPase and SERCA served for the purity of the mitochondrial preparation. The Cx43 content showed the difference between the two
mice strains. (B) The statistical evaluation of the Cx43 signal in SSM as related to the ATP-synthase a signal is present as mean  SEM (* signifi-
cance with P < 0.05 between wild-type and Cx43Cre-ER(T)/fl mice).
A B
Fig. 1Mitochondrial NOS expression in subsarcolemmal mitochondria of wild-type mice and Cx43Cre-ER(T)/fl mice. (A) Subsarcolemmal mitochondria
(SSM) isolated from the ventricles of Cx43Cre-ER(T)/fl and wild-type mice were stained with antibodies against nNOS or iNOS (red) and the mitochon-
drial marker cytochrome c (green) and analysed by confocal laser scanning microscopy. Merged image shows co-localization pixels in yellow. (B)
Amount in per cent of nNOS- and iNOS-positive SSM were referred to 100%. Individual preparations of n = 7. §P < 0.003 nNOS of wild-type versus
nNOS of Cx43Cre-ER(T)/fl, *P < 0.001 nNOS of wild-type versus iNOS of wild-type, #P < 0.02 iNOS of Cx43Cre-ER(T)/fl versus nNOS of Cx43Cre-ER(T)/fl,
$P < 0.002 iNOS of Cx43Cre-ER(T)/fl versus iNOS of wild-type.
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comparable with the nitric oxide production in SSM of wild-type mice
(Fig. 4C). Therefore, a contamination of mitochondria with cellular
NOS isoforms attached to the outer mitochondrial membrane as
explanation for the measured nitric oxide formation appeared unlikely
and an existence of nNOS-dependent mitochondrial nitric oxide pro-
duction was confirmed. Again the nitric oxide specificity of the signal
was shown by PTIO.
The NOS-dependent nitric oxide formation in Cx43Cre-ER(T)/fl mice
(0.14  0.02 nmol/min./mg, n = 12) was reduced in comparison to
wild-type mice (0.24  0.02 nmol/min./mg; Fig. 5). Inhibition of
nNOS by SMTC in SSM of wild-type mice strongly reduced the nitric
oxide formation (0.05  0.01 nmol/min./mg; Table 1). SMTC
showed a lower effect of reducing of nitric oxide formation in SSM of
Cx43Cre-ER(T)/fl mice (0.06  0.02 nmol/min./mg). In contrast,
1400 W reduced the nitric oxide formation in SSM of Cx43Cre-ER(T)/fl
to 62%. A similar result was detectable by iNOS inhibition in SSM of
wild-type mice (58% nitric oxide formation). The negative control
showed a residual NOS activity of 0.06  0.02 nmol/min./mg
(n = 4). The enzymatic residual NOS activity was completely reduced
by SMTC and 1400 W. To confirm the Cx43 dependence of the NOS
shift, we used isolated IFM of wild-type mice, the mitochondrial sub-
population without Cx43, as internal control [1]. The purity of IFM
preparation was controlled by Western blot analysis. IFM were not
contaminated with proteins of sarcolemma and sarcoplasmatic reticu-
lum as shown by the absence of Na+/K+-ATPase and SERCA immuno-
reactivity (Fig. 6A). Cx43 was also detected exclusively in SSM
(Fig. 6B).
Interfibrillar mitochondria showed a significantly reduced nitric
oxide formation (0.17  0.02 nmol/min./mg, n = 9) in contrast to
SSM (0.24  0.03 nmol/min./mg, n = 10; Fig. 7). In presence of
the nitric oxide scavenger PTIO, the nitric oxide formation was
almost undetectable in both mitochondrial preparations (0.007 
0.006 nmol/min./mg in SSM; 0.03  0.01 nmol/min./mg IFM;
Fig. 7).
Another independent method for quantifying nitric oxide formation
is the ESR technique. The ESR spectrum of the positive control
(GSNO) showed a prominent nitric oxide–Fe2+–MGD triplet (Fig. 8A).
In the SSM of wild-type mice, a basal spectrum of nitric oxide–Fe2+–
MGD triplet was detected (Fig. 8B). In the SSM of Cx43Cre-ER(T)/fl
mice, the intensity of the specific spectra of nitric oxide–Fe2+–MGD
complex was reduced compared to the wild-type mice (Fig. 8C). Peak
three is an indicator of the nitric oxide content in SSM of wild-type
and Cx43Cre-ER(T)/fl mice obtained from relative signal amplitudes of
nitric oxide–Fe2+–MGD complex. The nitric oxide content of peak
three in SSM of Cx43Cre-ER(T)/fl mice was significantly reduced com-
pared to wild-type mice (n = 6 preparations, Fig. 8D).
A
B C
Fig. 4 Nitric oxide formation in mitoplasts of wild-type mice. (A) Representative Western blot shows the difference between subsarcolemmal mito-
chondria (SSM, n = 5) and mitoplast (MP, n = 6) preparation by the absence of the outer mitochondrial membrane protein voltage-dependent anion
channel (VDAC). #P < 0.05 indicates the significant difference between MP and mitochondria. (B) Statistical evaluation presents the mean  SEM of
MP as related to SSM (in %), * significance with P < 0.05 MP and mitochondria. (C) Nitric oxide formation in MP (n = 11) and mitochondria
(n = 10). PTIO scavenged the accumulated nitric oxide. * Significance between SSM  PTIO (P < 0.001), ** significance between MP  PTIO
(P < 0.001).
Fig. 3 Basal nitric oxide formation in subsarcolemmal mitochondria of
wild-type mice. PTIO (n = 7) reduced the nitric oxide formation. The
enzymatic NOS inhibition by the inhibitors W7 (non-selective, n = 5)
and SMTC (nNOS selective, n = 7) reduced nitric oxide formation.
*P < 0.001 indicates significant difference after treatment with PTIO,
W7 or SMTC. Wild-type mice (n = 13).
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Discussion
In the present study, Cx43 expression correlated with the NOS iso-
form mainly present in SSM. While in SSM from wild-type hearts
nNOS was the main isoform, in SSM from Cx43-deficient mice hearts
iNOS dominated.
The constitutive mitochondrial NOS isoform expressed differs
among species. The iNOS was present in porcine and rat heart mito-
chondria [47, 48], while nNOS was mainly found to be expressed in
mitochondria from mice hearts [49]. The latter finding was confirmed
in the present study in SSM isolated from wild-type C57BL/6J mice.
In previous studies, also eNOS protein was localized to mitochon-
dria [50]; however, in the present study while we could detect an
eNOS signal in the vascular endothelium, there was no signal
detected in mitochondria (data not shown). More recently, increased
translocation of eNOS protein (located in caveolae) to the outer mito-
chondrial membrane was demonstrated upon short periods of ischae-
mia/reperfusion [51]. Thus, some of the differences observed in
mitochondrial eNOS expression might relate to the presence or
absence of attached sarcolemmal proteins which was excluded in our
mitochondrial preparation.
The mtNOS protein was mainly detected by immunohistochemical
[8, 52] and biochemical methods [48, 53–55]. Similarly, the presence
of mtNOS in the present study could only be confirmed by immuno-
histochemistry and direct measurement of nitric oxide formation from
isolated mitochondria; no specific NOS signal was detected by Wes-
tern blot using commercially available antibodies. One explanation for
the lack of detection of NOS expression in the Western blot analysis
is the limited sensitivity (1/10) in comparison to laser scan micros-
copy [56]. This assumption is supported by the fact that with massive
overexpression of nNOS in mice, a mitochondrial signal was detected
also by Western blot [57].
Given the lack of NOS detection in mitochondria by a method like
Western blot, the existence of NOS in mitochondria is still under dis-
cussion [58]. In different studies, mitochondrial NOS was attributed
to a contamination of the preparation or the attachment of NOS to the
outer mitochondrial membrane [59–61]. To circumvent this problem,
we generated mitoplasts [1] and the rate of nitric oxide formation of
mitoplasts was similar to that of intact SSM.
An array of methods exists for the detection of mtNOS-depen-
dent nitric oxide formation including photometrical (oxyhaemoglo-
bin assay, DAF-2 assay) [58, 62–64], electrochemical (porphyrinic
microsensor) [49] and radioactive (citrulline assay) techniques [7].
The sensitivity and specificity of the oxyhaemoglobin assay is suf-
ficient to detect mtNOS-dependent changes in nitric oxide forma-
tion [48, 49, 58, 65] and allows real-time detection of generated
nitric oxide [66]. In the present study, we were able to confirm
the rate of NOS-derived basal nitric oxide formation in the SSM
from wild-type hearts. The nitric oxide formation of about
0.24 nmol/min. mg and was thus close to the range of NOS-
derived nitric oxide formation rates from rat heart mitochondria
(0.37 nmol/min./mg and 0.69 nmol/min./mg) [48, 65, 67]. Compo-
sition of the buffer, the temperature and the mitochondrial meta-
bolic state could cause the small differences in basal nitric oxide
formation. However, the specificity of the detected nitric oxide sig-
nal was proven by scavenging nitric oxide through addition of
Table 1 Nitric oxide formation after nitric oxide synthase inhibition in all mice strains
Mice strains
Nitric oxide formation (nmol/min./mg)
Basal After nNOS inhibition (SMTC) After iNOS inhibition (1400 W)
Wild-type 0.24  0.02 0.05  0.01* 0.13  0.01*
Cx43Cre-ER(T)/fl 0.14  0.02 0.06  0.01† 0.05  0.02†
nNOS/ 0.06  0.02 0.03  0.01‡ 0.009  0.009‡
*Wild-type  SMTC (P < 0.001) and 1400 W (P < 0.001).
†Cx43Cre-ER(T)/fl  SMTC (P < 0.001) and 1400 W (P < 0.001).
‡nNOS/ mice  SMTC (P < 0.005) and 1400 W (P < 0.001).
SMTC, S-methyl-thiocitrulline, iNOS, inducible nitric oxide synthase; nNOS, neuronal nitric oxide synthase.
Fig. 5Mitochondrial nitric oxide formation and connexin 43 deficiency.
Comparison of nitric oxide formation in subsarcolemmal mitochondria
(SSM) of wild-type (n = 15) and Cx43Cre-ER(T)/fl mice (n = 12,
*P < 0.001). NNOS/ mice served as negative controls (n = 4). #
indicates the significant difference between wild-type and nNOS/ mice
(P < 0.001).
820 ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
PTIO. The strong reduction of the nitric oxide formation by selec-
tive nNOS inhibition confirmed a mainly expressed mitochondrial
nNOS in wild-type mice. The slight reduction of the nitric oxide
formation by the selective iNOS inhibitor approved a small amount
of active mitochondrial iNOS in wild-type mice.
Concomitant with an enhanced mitochondrial iNOS expression, an
increased nitric oxide formation rate was expected. However, and to
our surprise, the enhanced mitochondrial iNOS and reduced mito-
chondrial nNOS expression in Cx43-deficient hearts was associated
with a reduced rate of nitric oxide formation in mitochondria derived
from Cx43-deficient mice hearts. These data from the oxyhaemoglo-
bin assay were confirmed by a second independent technique, namely
ESR, which also shows a high nitric oxide sensitivity [68].
Indeed, iNOS may be present in two forms either as uncoupled
monomer and/or coupled dimer. Zhang et al., found in a stress-
induced myocardium of wild-type mice, both iNOS monomer and
iNOS dimer [69]. One can speculate that the reduced nitric oxide for-
mation in mitochondria from Cx43-deficient mice relates to the pres-
ence of an enhanced monomer iNOS isoform and coincident low
dimer iNOS isoform.
Mitochondrial nitric oxide formation in nNOS/ mice (negative
control) was because of an enzymatic residual activity of the conceiv-
ably available splice variants nNOS-b und nNOS-c [70, 71], which
were inhibited to a great extent by the selective nNOS inhibitor, and
some contribution of iNOS. The remaining nitric oxide formation
might represent non-enzymatically released nitric oxide from nitrite
[72], which have been suggested to contribute to the cardioprotective
effect of nitrite [73, 74].
Nitrosylation of several respiratory complexes including complex I
are supposed to impair respiration [25]. Indeed, IFM which have a
lower nitric oxide production as compared to SSM have a higher
respiratory rate. Although SSM of Cx43-deficient mice also have a
reduced nitric oxide production as compared to SSM of wild-type
mice, they nevertheless have a reduced respiratory rate and ATP pro-
duction [75]. One potential explanation for this contradictory finding
might relate to decreased potassium flux in Cx43-deficient mice upon
ADP stimulation, which impairs matrix volume recovery and thus
mitochondrial oxygen consumption [76].
Indeed, we have recently shown that increased S-nitrosation of
Cx43 enhanced potassium influx into the mitochondrial matrix as well
as the generation of reactive oxygen species [77], the latter being an
important signalling molecule for endogenous cardioprotection.
Importantly, in the above study, ischaemic preconditioning increased
S-nitrosation of mitochondrial Cx43. The present study adds one
more facet to the interaction of nitric oxide and Cx43 in that the
mtNOS isoform and subsequently the mitochondrial nitric oxide pro-
duction depends on the level of Cx43 expression (Fig. 9). An overall
reduction of Cx43 expression in Cx43-deficient mice not only reduced
mitochondrial Cx43 but also mitochondrial nNOS expression with a
subsequent decrease in mitochondrial nitric oxide production and
overall protein S-nitrosation (Data S1), both contributing to a reduction
A B
Fig. 6 Content of connexin 43 in subsarcolemmal and interfibrillar mitochondria. (A) Representative Western blot of Cx43 in isolated subsarcolem-
mal (SSM, n = 5) and interfibrillar (IFM, n = 5) mitochondria from left ventricles (LV). SERCA and Na+/K+-ATPase served as marker protein for the
purity of the mitochondrial preparation. Ponceau S staining shows equal protein loading. (B) Quantification of the Cx43 content in SSM and IFM nor-
malized to Ponceau S staining (n = 5 individual preparations, *P < 0.001).
Fig. 7 Nitric oxide formation in subsarcolemmal and interfibrillar mito-
chondria. Nitric oxide formation was compared between subsarcolem-
mal (SSM, n = 10 individual experiments) and interfibrillar mitochondria
(IFM, n = 9 individual experiments) of wild-type mice (#P < 0.04
between SSM and IFM). Isolated IFM served as internal control. Nitric
oxide specificity was shown by PTIO. *P < 0.001 SSM  PTIO,
§P < 0.001 IFM  PTIO.
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of mitochondrial matrix potassium influx and reactive oxygen species
formation upon an external stimulus such as ischaemic or pharmaco-
logical preconditioning thereby contributing to the lack of endogenous
cardioprotection seen in Cx43-deficient mice [78, 79].
In conclusion, the present study showed that reduced mitochondrial
Cx43 content is associated with a switch of the mitochondrial NOS
isoform and the respective mitochondrial nitric oxide production rate.
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